A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants

PHASE3CompletedINTERVENTIONAL
Enrollment

648

Participants

Timeline

Start Date

March 12, 2024

Primary Completion Date

June 11, 2025

Study Completion Date

June 11, 2025

Conditions
Respiratory Syncytial Virus
Interventions
BIOLOGICAL

RSVpreF vaccine

RSVpreF vaccine

BIOLOGICAL

Placebp

Placebo

Trial Locations (14)

1459

REIMED Reiger Park, Boksburg

1500

Worthwhile Clinical Trials, Benoni

2001

Wits RHI, Johannesburg

2013

University of Witwatersrand (WITS) - Vaccines and Infectious Diseases Analytics (VIDA), Johannesburg

2093

Wits VIDA Nkanyezi Research Unit, Johannesburg

3370

Qhakaza Mbokodo Research Clinic, Ladysmith

5241

Synergy Biomed Research Institute, East London

6850

FAMCRU - Worcester, Worcester

7700

MRC Unit on Child And Adolescent Health, Cape Town

7750

Gugulethu Green Clinic, Cape Town

9301

Josha Research, Bloemfontein

0152

Setshaba Research Centre, Pretoria

0184

Botho Ke Bontle Health Services, Pretoria

0699

Gole Biomed Research Centre, Polokwane

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT06325657 - A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants | Biotech Hunter | Biotech Hunter